References
- Petitou M, Casu B, Lindahl U. 1976–1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie. 2003;85(1–2):83–89.
- Razi N, Feyzi E, Björk I, et al. Structural and functional properties of heparin analogues obtained by chemical sulphation of Escherichia coli K5 capsular polysaccharide. Biochem J. 1995;309:465–472.
- Rabenstein DL. Heparin and heparan sulfate: structure and function. Nat Prod Rep. 2002 Jun;19(3):312–331.
- Couch NP. About heparin, or … whatever happened to Jay McLean? J Vasc Surg. 1989;10(1):1–8.
- Jorpes JE. Heparin: a mucopolysaccharide and an active antithrombotic drug. Circulation. 1959;19(1):87–91.
- Nader HB, Straus AH, Takahashi HK, et al. Selective appearance of heparin in mammalian tissues during development. Biochim Biophys Acta. 1982;714(2):292–297.
- Barrowcliffe TW. History of heparin. Handb Exp Pharmacol. 2012;207:3–22. doi:10.1007/978-3-642-23056-1_1
- Levieux A, Rivera V, Levieux D. Immunochemical control of the species origin of porcine crude heparin and detection of ovine and caprine materials. J Pharm Biomed Anal. 2002;27(1–2):305–313.
- Ye H, Toby TK, Sommers CD, et al. Characterization of currently marketed heparin products: key tests for LMWH quality assurance. J Pharm Biomed Anal. 2013;85:99–107.
- Xiao Z, Tappen BR, Ly M, et al. Heparin mapping using heparin lyases and the generation of a novel low molecular weight heparin. J Med Chem. 2011;54(2):603–610.
- Liu H, Zhang Z, Linhardt RJ. Lessons learned from the contamination of heparin. Nat Prod Rep. 2009;26(3):313–321.
- FDA warning letter; [cited 2008 Apr 21]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm054109.pdf
- Potential Health & Safety Impacts from Pharmaceuticals and Supplements Containing Chinese-Sourced Raw ingredients [Internet]. [cited 2008 Apr 21]. Available from: http://origin.www.uscc.gov/sites/default/files/Research/NSD_BIO_Pharma_Report–Revised_FINAL_for_PDF–14_%20April_2010.pdf
- McMahon AW, Pratt RG, Hammad TA, et al. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008. Pharmacoepidemiol Drug Saf. 2010;19(9):921–933.
- Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf. 2009;8(2):129–144.
- Hattersley PG. Activated coagulation time of whole blood. JAMA. 1966;196(5):436–440.
- Ganter MT, Monn A, Tavakoli R, et al. Kaolin-based activated coagulation time measured by sonoclot in patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2007;21(4):524–528.
- Despotis GJ, Gravlee G, Filos K, et al. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology. 1999;91(4):1122–1151.
- Bosch YP, Ganushchak YM, de Jong DS. Comparison of ACT point-of-care measurements: repeatability and agreement. Perfusion. 2006;21(1):27–31.
- Vonk AB, Veerhoek D, van den Brom CE, et al. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery. J Cardiothorac Vasc Anesth. 2014;28(2):235–241.
- Despotis GJ, Avidan MS, Hogue CW Jr. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg. 2001;72(5):S1821–1831.
- Shapira OM, Korach A, Pinaud F, et al. Safety and efficacy of biocompatible perfusion strategy in a contemporary series of patients undergoing coronary artery bypass grafting – a two-center study. J Cardiothorac Surg. 2014;9:196.
- STS Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011;91(3):944–982.
- Claudot F, Alla F, Fresson J, et al. Ethics and observational studies in medical research: various rules in a common framework. Int J Epidemiol. 2009;38(4):1104–1108.
- Ranucci M, Bozzetti G, Ditta A, et al. Surgical reexploration after cardiac operations: why a worse outcome? Ann Thorac Surg. 2008;86:1557–1562.
- Dunning J, Versteegh M, Fabbri A, et al.; EACTS Audit and Guidelines Committee. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg. 2008;34:73–92.
- Arsenault KA1, Paikin JS, Hirsh J, et al. Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. J Thorac Cardiovasc Surg. 2012 Oct;144(4):944–950.